Microbion is a clinical-stage pharmaceutical company founded with the mission to develop innovative therapeutic solutions for difficult-to-treat bacterial infections, including chronic and antibiotic-resistant infections. The company focuses on creating best-in-class, novel medicines that address key unmet medical needs, aiming to provide physicians with breakthrough options to improve and extend patients' lives. Microbion's lead therapeutic candidate, Pravibismane, exemplifies their commitment to combating challenging infections.

Notable affiliated individuals include the company's leadership team and scientific advisors who bring extensive expertise in pharmaceuticals and biotechnology. Microbion has garnered attention from investors interested in pioneering healthcare solutions. Key achievements include advancing Pravibismane through various stages of clinical trials, demonstrating its potential efficacy and safety. Overall, Microbion's impact lies in its dedication to transforming infection treatment paradigms and addressing significant gaps in current medical therapies.